Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Novo Nordisk’s blockbuster weekly injectable formulation of semaglutide — Ozempic — has secured an even more formidable label. Apart from its ability to stimulate insulin production in patients with diabetes, the FDA has now also endorsed its ability to reduce the risk of major adverse cardiovascular events.
Patients with diabetes are often afflicted with other comorbidities, such as obesity, CV disease, and kidney problems. Diabetes drugmakers have been clamoring for a broader market share by differentiating their drugs on the basis of therapeutic impact on these intersecting indications — but the major, most lucrative battleground is the heart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.